The Company's lead therapeutic will be
available through a newly opened compassionate
use program
EDINBURGH, Scotland, May 15, 2024
/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the
"Company") (NASDAQ: TCBP) a clinical stage biotechnology
company developing platform allogeneic gamma-delta T cell therapies
for cancer and other indications, today announced that the
company's lead therapeutic TCB008 will be available to patients via
a newly launched compassionate use program in the UK.
Compassionate use refers to the prescription of unlicensed
medicinal products to treat a patient in instances where their
individual clinical needs cannot be met with the available licensed
treatments. Patients enrolling in these clinical trials must meet
specific entry criteria, both to protect vulnerable patient
populations and ensure the validity of study data. These data must
be reviewed and approved by regulatory agencies before products can
be marketed as licensed medicinal products for patient
treatment.
Access to TCB's cell therapy products through the compassionate
use program will provide medical practitioners with treatment
options for patients who are ineligible to access experimental
treatments through ongoing clinical trials.
"TCBP firmly believes in putting patients' needs first, not just
extending life but providing a higher quality of life for patients
who might otherwise have no other options for treatment. We are
immensely appreciative of the support and effort from our physician
investigators leading to expanded access to TCB008 to support the
treatment of patients with clinical needs that cannot currently be
met with licensed treatments," said Mr. Bryan Kobel, CEO of TC BioPharm. "In addition to
helping patients, this step will increase our data set and
knowledge around TCB-008 and inform a broader use case as a
therapeutic in the future. Initiating this program is yet another
leap forward for TCBP and another milestone achieved, and
concurrently to our ongoing Phase 2b
clinical trial, as we remain committed to advancing the
availability and potential of cell therapies."
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this Current Report on Form 8-K
that do not relate to matters of historical fact should be
considered forward-looking statements, including without limitation
statements regarding the Company's intent or ability to affect any
budget savings or execute on any M&A or capital raising
strategy. These statements are based on management's current
assumptions and are neither promises nor guarantees, but involve
known and unknown risks, uncertainties and other important factors
that may cause the Company's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. For other important factors that could
cause actual results to differ materially from the forward-looking
statements in this Current Report on Form 8-K, please see the risks
and uncertainties identified under the heading "Risk Factors" in
our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed
with the SEC, all of which is available on the Company's Investor
Relations website at www.tcbiopharm.com and on the SEC website at
www.sec.gov. All forward-looking statements reflect the Company's
beliefs and assumptions only as of the date of this Current Report
on Form 8-K. The Company undertakes no obligation to update
forward-looking statements to reflect future events or
circumstances.
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of
gamma-delta T cell therapies for the treatment of cancer with human
efficacy data in acute myeloid leukemia. Gamma-delta T cells are
naturally occurring immune cells that embody properties of both the
innate and adaptive immune systems and can intrinsically
differentiate between healthy and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell
therapies, and the first company to conduct phase II/pivotal
clinical studies in oncology. The Company is conducting two
investigator-initiated clinical trials for its unmodified
gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of
acute myeloid leukemia using the Company's proprietary allogeneic
CryoTC technology to provide frozen product to clinics
worldwide.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tcbp-announces-launch-of-compassionate-use-program-for-tcb008-302146243.html
SOURCE TC BioPharm
